Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

CapMan Q3’25: Light at the end of the tunnel in the fundraising market

CapMan

CapMan’s Q3 was slightly better than expected. Q3 revenue grew clearly due to the acquisitions completed earlier in the year. Management fees and wealth management fees developed slightly better than we expected, and overall, the fee mix was better than we expected. Analyst Sauli Vilén summarizes.

Read the latest company report here.

Stay up to date
Analyst Interviews

Recent videos

Herantis Pharma Plc, Phase 1b biomarker data webcast
2026-01-08 11:00 Herantis Pharma
Investor Day | Nov. 24, 2025
2025-12-23 11:00 United Bankers
Uppesittarkväll 22/12 från Inderes Event Studio
2025-12-22 20:00
Talenom - Planned demerger and strategies of Talenom and Easor
2025-12-18 11:00 Talenom
Conference call with Fabege´s new CEO Bent Oustad
2025-12-18 10:00 Fabege
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.